Alnylam Pharmaceuticals, Inc. (ALNY) › Analysis

Alnylam Pharmaceuticals (ALNY) stock analysis, November 3, 2026: Demand doubts crush shares; downtrend intact near 52-week low

Published November 3, 2026 · ALNY chart, levels and live analysis

Alnylam Pharmaceuticals (ALNY) has lost about 30% of its value in five days after third-quarter results showed Amvuttra demand growing more slowly than hoped. The balance of evidence stays negative, with high conviction. At $160.42 the stock sits just above its 52-week low of $158.00 and below both its 50-day and 200-day averages, while healthcare as a whole rose. The fall is almost entirely the stock's own, and deeply oversold conditions are the main reason the picture is not one-sided.

Why it matters

The business is still growing quickly, but not as fast as the price needed. On October 29, 2026, Alnylam reported third-quarter product revenue of about $1.3 billion, up 52% from a year earlier, and The Motley Fool's transcript puts Amvuttra sales at $1.13 billion, up 65%. Management kept its 2026 TTR sales guidance of $4.2 billion to $4.5 billion but said results should land at the low end because demand growth is slower than expected, according to Seeking Alpha. That follows the July 30 guidance cut of roughly $200 million, which sent shares down 28.31% to $205.48 and has since drawn a run of law-firm investigations, such as the one announced by the Law Offices of Howard G. Smith.

So the market had already been burned once on this exact question, whether the ATTR-CM market is growing or normalizing. The stock had fallen 46% over six months and was down 35% from its September 30 close of $246.74 before this report. A second "low end of the range" message told holders that the July reset was not the last one. The reaction was a further drop of roughly 30% in five days. By October 30 the shares were near $174, which BMO noted as a 22% weekly decline, and they have slid further since.

Almost none of this came from the market or the sector. Over five days ALNY fell 29.6%, the S&P 500 fell 2.1%, and the healthcare ETF XLV rose 2.8%. That leaves the stock 32.4 points behind its sector, so the cause is company-specific and the news explains it. Healthcare led the week, as Morningstar's weekly update shows, and ALNY fell anyway.

Analysts are split on whether the cut is permanent. Truist downgraded the stock to hold on November 2, cutting its target to $225 from $315 and trimming its 2027 Amvuttra forecast by about 12%. On the other side, UBS kept a Buy with a $329 target, noting Amvuttra sales were in line with consensus though below its own estimate. Raymond James reiterated Strong Buy at $420 before the report, citing pipeline data. Across 27 analysts the consensus is still buy, with a mean target of $302.48, 47% above the price. The lowest target, $180, is also above the price. Targets have been cut but not by enough to meet the market, which suggests the sell-side is still catching up to the stock's own verdict.

What the evidence says

The long-term trend is down, and the thesis is weakened rather than broken. The stock is below its 40-week average and 66% under its 52-week high of $473.29. It is down 59.8% this year while the S&P 500 is up 10.5%. Revenue is still growing at a pace most companies would envy, so this is a fight about the rate of growth and the multiple paid for it, not about whether the drug works. The stock is in the late, disorderly stage of a markdown, after a gap down on earnings.

For the next two to six weeks, the evidence leans negative with high conviction, three of four points. The daily trend runs with the weekly downtrend. ALNY lags the S&P 500 by 30.1% over 50 days and XLV by 35.8%. The price is below the 50-day average at $233.42 and the 200-day at $283.48, so every rally has overhead supply to work through.

The strongest case against is the bounce. The 14-day RSI is 21.85, a deeply oversold level, the stock rose 1.5% today, and it sits 1.5% above its 52-week low. Reported revenue growth is strong, and the consensus target is far above the price. Stocks this stretched often rally sharply. That is why conviction is not higher, but a bounce is not a change of trend. Nothing in the weekly or daily trend has turned, and the first resistance is overhead at $175.

Levels that matter

In a downtrend the structure is defined from above. The stock holds below $175.00, a round number where sellers have shown up on rallies, and the $200 mark and the 50-day average at $233.42 sit above it. The weekly trend would end only above $272.59, a swing zone just under the 200-day average at $283.48, so a recovery of that size would need to be a major shift.

The breakout level is a daily close below $158.00, the 52-week low. From there the first target is $150, which gives 0.4 to 1 against a stop at $178.01 (the $175 round level plus a quarter of ATR). The second is $125, which gives 1.6 to 1. The math does not reach 3 to 1. It would take a target well below $125 or a much tighter stop, and the map offers neither. Even with the trend pointing down, the risk to a breakout is poorly paid.

What would change the picture

A weekly close above $272.59 would end the downtrend. The non-price fact that could do it is evidence that Amvuttra demand has re-accelerated, such as quarterly sales that beat consensus or a 2026 TTR outlook moved off the low end of the $4.2 billion to $4.5 billion range. That would answer the question that has driven both the July and October declines.

What to watch

Get a message when the ALNY picture changes — the agent team watches the levels and the news for you.Create a free account

More ALNY analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.